Robbins Arroyo LLP: Heron Therapeutics, Inc. (HRTX) Misled Shareholders According to a Recently Filed Lawsuit

Jun 07, 2019 12:12 pm

SAN DIEGO --

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Heron Therapeutics, Inc. (NASDAQ: HRTX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 31, 2018 and April 30, 2019. Heron Therapeutics is a biotechnology company that develops treatments to address unmet medical needs. HTX-011 is one of the drugs Heron is developing.

View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/heron-therapeutics-inc/

Heron Therapeutics Accused of Misleading Investors

According to the complaint, in October 2018, Heron announced the submission of its New Drug Application ("NDA") for HTX-011 to the U.S. Food and Drug Administration ("FDA") for post-operative pain management. It touted the data it used to support the filing. Heron's CEO went further by promoting Heron's prior experience with filing NDAs, as well as its close working relationship with the FDA. However, Heron failed to disclose that the HTX-011 NDA did not contain adequate information. In May 2019, Heron revealed that HTX-011 had failed to gain FDA approval because it lacked sufficient information. Specifically, the FDA denied HTX-011's NDA purely based on Heron's failure to include the requisite CMC and non-clinical information. On this news, Heron's stock price fell over 18% to close at $17.75 per share on May 1, 2019, and has yet to recover.

Heron Therapeutics Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leo Kandinov at (800) 350-6003, [email protected] or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005390/en/

Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
[email protected]
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Return to Top

Disclaimer :: Use of this site is subject to, and your continued use constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information. INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion; however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR® or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment. Users should always consult with and obtain advice from their professional licensed financial advisor, including their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment or trading securities do so with caution. Users should perform full due diligence and investigate any security fully before making an investment or before the execution of a security trade based upon information learned through INK. Investors should obtain annual reports and other company information to complete their own due diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this website. On this site, there may be third party content, content from authors or links to third-party sites or pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI® is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.

Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.

You are here

Robbins Arroyo LLP: Heron Therapeutics, Inc. (HRTX) Misled Shareholders According to a Recently Filed Lawsuit